4893 items matching your search terms.

Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial

Duchesne, G. M. Woo, H. H. Bassett, J. K. Bowe, S. J. D'Este, C. Frydenberg, M. King, M. Ledwich, L. Loblaw, A. Malone, S. Millar, J. Milne, R. Smith, R. G. Spry, N. Stockler, M. Syme, R. A. Tai, K. H. Turner, S.
LANCET ONCOLOGY, 2016     DOI:10.1016/S1470-2045(16)00107-8

Molecular markers of beta-cell mortality

Farr, R.J. Joglekar, M.V. Januszewski, A.S. Akil, A.S. Taylor, C.J. Cotta, V. Craig, M. Jenkins, A. Hardikar, A.A.

TACTIC: a multicentre, open-label, single-arm phase II trial of panitumumab, cisplatin, and gemcitabine in biliary tract cancer

Ferraro, D. Goldstein, D. O'Connell, R. L. Zalcberg, J. R. Sjoquist, K. M. Tebbutt, N. C. Grimison, P. McLachlan, S. Lipton, L. L. Vasey, P. Gebski, V. J. Aiken, C. Cronk, M. Ng, S. Karapetis, C. S. Shannon, J. behalf of the the Australasian Gastro-Intestinal Trials, Group
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2016     DOI:10.1007/s00280-016-3089-4

Comparison between site and central radiological assessments for patients with recurrent glioblastoma on a clinical trial

Field, K. Fitt, G. Simes, J. Nowak, A Barnes, E. Sawkins, K. Goh, C. Moffat, B.A. Salinas, S. Cher, L. Wheeler, H. Hovey, E. Rosenthal, M. Phal, P.

Health-related quality of life outcomes from cabaret: A randomized phase 2 trial of carboplatin and bevacizumab in recurrent glioblastoma

Field, K. King, M. Simes, J. Espinoza, D. Barnes, E. Sawkins, K. Rosenthal, M. Cher, L. Hovey, E Wheeler, H. Nowak, A.

Evolving management of low grade glioma: No consensus amongst treating clinicians

Field, K. M. Rosenthal, M. A. Khasraw, M. Sawkins, K. Nowak, A. K.
JOURNAL OF CLINICAL NEUROSCIENCE, 2016     DOI:10.1016/j.jocn.2015.05.038

CD151 Gene and Protein Expression Provides Independent Prognostic Information for Patients with Adenocarcinoma of the Esophagus and Gastroesophageal Junction Treated by Esophagectomy

Fisher, O. M. Levert-Mignon, A. J. Lehane, C. W. Botelho, N. K. Maag, J. L. Thomas, M. L. Edwards, M. Lord, S. J. Bobryshev, Y. V. Whiteman, D. C. Lord, R. V.
ANNALS OF SURGICAL ONCOLOGY, 2016     DOI:10.1245/s10434-016-5504-9

Survival outcomes of supportive care versus dialysis therapies for elderly patients with end-stage kidney disease: A systematic review and meta-analysis

Foote, C. Kotwal, S. Gallagher, M. Cass, A. Brown, M. Jardine, M.
NEPHROLOGY (CARLTON), 2016     DOI:10.1111/nep.12586

Dose Escalation of Tamoxifen in Patients with Low Endoxifen Level: Evidence for Therapeutic Drug Monitoring-The TADE Study

Fox, P. Balleine, R. L. Lee, C. Gao, B. Balakrishnar, B. Menzies, A. M. Yeap, S. H. Ali, S. S. Gebski, V. Provan, P. Coulter, S. Liddle, C. Hui, R. Kefford, R. Lynch, J. Wong, M. Wilcken, N. Gurney, H.
CLINICAL CANCER RESEARCH, 2016     DOI:10.1158/1078-0432.CCR-15-1470

Prognostic value of isolated peritoneal versus other metastatic sites in colorectal cancer patients treated by systemic chemotherapy: findings from 9,265 patients in the ARCAD database

Franko, J. Shi, Q. Meyers, J.P. Heinemann, V. Falcone, A. Tebbutt, N.C. Maughan, T. Seymour, M. Saltz, L. Tournigand, C. Diaz-Rubio, E. Sougklakos, I. Chibaudel, B. Moen, J. De Gramont, A. Adams, R.A. Sargent, D.J. Grothey, A.

Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database

Franko, J. Shi, Q. Meyers, J. P. Maughan, T. S. Adams, R. A. Seymour, M. T. Saltz, L. Punt, C. J. A. Koopman, M. Tournigand, C. Tebbutt, N. C. Diaz-Rubio, E. Souglakos, J. Falcone, A. Chibaudel, B. Heinemann, V. Moen, J. De Gramont, A. Sargent, D. J. Grothey, A. Analysis, Research in Cancers of the Digestive System, Group
LANCET ONCOLOGY, 2016     DOI:10.1016/S1470-2045(16)30500-9

Patient-reported outcomes (PRO) in ovarian cancer clinical trials-lost opportunities and lessons learned

Friedlander, M. Mercieca-Bebber, R. L. King, M. T.
ANNALS OF ONCOLOGY, 2016     DOI:10.1093/annonc/mdw080

Efficacy of a novel antibody-drug conjugate, ABT-414, as monotherapy in epidermal growth factor receptor (egfr) amplified, recurrent glioblastoma

Gan, H. Van Den Bent, M. Lassman, A.B. Kumthekar, P. Merrell, R. Butowski, N. Lwin, Z. Mikkelsen, T. Nabors, L.B. Papadopoulos, K.P. Penas-Prado, M. Simes, J. Wheeler, H. Gomez, E. Reardon, D. Lee, H.J. Roberts-Rapp, L. Xiong, H. Bain, E. Holen, K.

Refining the care of patients with pancreatic cancer: the AGITG Pancreatic Cancer Workshop consensus

Gandy, R. C. Barbour, A. P. Samra, J. Nikfarjam, M. Haghighi, K. Kench, J. G. Saxena, P. Goldstein, D.

Serous ovarian and primary peritoneal cancers: a comparative analysis of clinico-pathological features, molecular subtypes and treatment outcome

Gao, B. Lindemann, K. Anderson, L. Fereday, S. Hung, J. Alsop, K. Tothill, R. Gebski, V. Kennedy, C. Balleine, R.L. Harnett, P.R. Bowtell, D DeFazio, A Australian Ovarian Cancer Study Group,